 AIM ImmunoTech Inc NYSE:AIM AIM announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands that will evaluate the potential of AIMs Ampligen rintatolimod in combination with AstraZenecas Imfinzi durvalumab for the treatment of pancreatic cancer. Ampligen is AIMs dsRNA drug currently being developed for globally important cancers. 